Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jin Medical InternationalZJYL 64 ROE % is 8.90% as of Sep. 2025, which is 46% below its 10-year median of 16.59. GuruFocus rates ZJYL with a GF Score™ of 64/100 and a GF Value™ of $14.58 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Jin Medical International ranks better than 56.07% on this metric.
The historical rank and industry rank for Jin Medical International's ROE % or its related term are showing as below:
ZJYL'
s ROE % Range Over the Past 10 Years
Min: 4.07 Med: 16.59 Max: 21.2
Current: 4.14
During the past 6 years, Jin Medical International's highest ROE % was 21.20%. The lowest was 4.07%. And the median was 16.59%.
ZJYL's ROE % is ranked better than 56.07% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.54
vs ZJYL: 4.14
Jin Medical International (NAS:ZJYL) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Sep. 2025) net income data. The Revenue data used here is two times the semi-annual (Sep. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Jin Medical International's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jin Medical International ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Jin Medical International's ROE % distribution charts can be found below:
* The bar in red indicates where Jin Medical International's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Sep. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Jin Medical International (ZJYL) has a ROE % of 8.90% as of Sep. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Jin Medical International and its competitors. This is 46% below median its historical median of 16.59. Over the past decade, Jin Medical International's ROE % has ranged from 4.07 to 21.20. According to the industry distribution chart, Jin Medical International ranks #351 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 43.9%.
Is Jin Medical International's ROE % too high?
Jin Medical International's current ROE % of 8.90% is 46% below median its 10-year median of 16.59. Over the past 10 years, this metric has ranged from a low of 4.07 to a high of 21.20. The Medical Devices & Instruments industry median ROE % is 2.54. Jin Medical International's value of 8.90% is 250.4% above this industry median. Based on the distribution chart, Jin Medical International ranks #351 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Jin Medical International has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jin Medical International's ROE % compare to RVP and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Jin Medical International ranks #351 out of 799 companies for ROE %. This puts Jin Medical International in the upper half of its industry. The industry median ROE % is 2.54. Jin Medical International's value of 8.90% is 250.4% above this benchmark. Historically, Jin Medical International's own ROE % has ranged from 4.07 to 21.20 over the past decade. While the company's 10-year median is 16.59 vs. the industry median of 2.54, Jin Medical International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.54, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jin Medical International's current ROE % of 8.90% is 250.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Jin Medical International and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jin Medical International's current ROE % is 8.90%, which is 46% below median its own 10-year median of 16.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jin Medical International stock overvalued right now?
Based on GuruFocus' analysis, Jin Medical International (ZJYL) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.58, compared to a current price of $1.96 — trading 86.6% below its estimated fair value. The current ROE % is 8.90%, which is 46% below median its 10-year median of 16.59 and 250.4% above the Medical Devices & Instruments industry median of 2.54. Jin Medical International's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Jin Medical International (ZJYL), the current ROE % is 8.90% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jin Medical International (ZJYL) Overvalued in 2026?
Based on GuruFocus' analysis, Jin Medical International stock appears to be undervalued.
The current stock price of $1.96 is trading 86.6% below its estimated GF Value™ of $14.58.
GuruFocus considers Jin Medical International to be Significantly Undervalued.
Key valuation signals for ZJYL:
ROE %: 8.90% (46% below median its 10-year median of 16.59)
GF Value™: $14.58 vs. price of $1.96 (86.6% below fair value)
Industry Position: 250.4% above the Medical Devices & Instruments median (#351 of 799)
No single metric tells the full story. See the ZJYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
64GF Score
Get the complete analysis for ZJYL
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZJYL has been successfully added to your 
